Pilot trial of tumor‐specific peptide vaccination and continuous infusion interleukin‐2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: An inter‐institute NIH study†
Medical and Pediatric Oncology2002Vol. 38(3), pp. 158–164
Citations Over TimeTop 10% of 2002 papers
Ramzi Dagher, Lauren Long, Elizabeth J. Read, Susan F. Leitman, Charles S. Carter, Maria Tsokos, Theresa J. Goletz, Nilo A. Avila, Jay A. Berzofsky, Lee J. Helman, Crystal L. Mackall
Abstract
Peptide vaccination as administered in this trial did not alter the dismal clinical outcome for patients with recurrent pediatric sarcomas. Future trials of tumor vaccines in this population should target patient populations with improved immune competence and smaller tumor burdens. Furthermore, optimization of the antigen presenting cell populations may be important for inducing immune responses to peptide antigens.
Related Papers
- → Protein kinase C iota as a therapeutic target in alveolar rhabdomyosarcoma(2012)31 cited
- → Preclinical Testing of Erlotinib in a Transgenic Alveolar Rhabdomyosarcoma Mouse Model(2011)13 cited
- → Clinical Relevance of Molecular Diagnosis in Childhood Rhabdomyosarcoma(2000)37 cited
- → Refractory alveolar rhabdomyosarcoma in an 11-year-old male(2021)3 cited
- → Alveolar Sinonasal Rhabdomyosarcoma in Adults: A Case Report(2013)